Research boost to improve outcomes for melanoma patients
11 October 2017
More than $3.5 million in competitive funding grants have been awarded to researchers at Melanoma Institute Australia as part of the National Health and Medical Research Council’s (NHMRC) funding outcomes, announced today.
In partnership with The University of Sydney, the boost will support a Practitioner Fellowship, a Career Development Fellowship and a Centre of Research Excellence aimed at driving better outcomes in melanoma.
MIA’s Co-Medical Director, Professor Richard Scolyer, was awarded a Practitioner Fellowship that will aim to utilise the extensive resources at MIA to improve outcomes of patients with difficult and aggressive melanomas.
Epidemiologist Associate Professor Anne Cust received a Career Development Fellowship for her research into skin cancer epidemiology, prevention and screening that will lead to improved patient and population health through impacting clinical practice and health policy.
Chair of MIA’s Research Committee Professor Graham Mann was awarded the Centre of Research Excellence in Melanoma grant. The project will identify the best way to conduct surveillance of high-risk melanoma patients, how to manage a person with melanoma who has a high potential for relapse, and how best to improve support, survivorship and the patient experience.
The funding will help facilitate MIA’s world-leading researchers to continue their ground-breaking work in melanoma research in order to improve outcomes for patients and their families.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.